Editorial Comment

The Prostate Cancer Prevention Trial (PCPT) suggested that finasteride could prevent prostate cancer, but it raised concerns about an increased risk of high-grade tumors, which limited its widespread use. The REDUCE trial, presented by Dr. Andriole, showed that dutasteride reduced prostate cancer incidence by 23% in high-risk men. The study emphasized the importance of standardized investigator training and central pathology processing in improving the quality of TRUS-guided prostatic biopsies. It highlighted significant variability in biopsy quality across international centers and validated the positive impact of uniform procedures on cancer detection rates. The large sample size of the REDUCE trial provided the statistical power to confirm these findings globally.